Search Results
May 23, 2026, 09:43 ET Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
May 22, 2026, 18:54 ET GOSS Investor Alert - Gossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization
More news about: Robbins LLP
May 22, 2026, 14:51 ET Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GOSS) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
May 21, 2026, 15:10 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GOSS
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-gossamer-bio-inc-of-class-action-lawsuit-and-upcoming-deadlines--goss-302779323.htmlSOURCE
More news about: Pomerantz LLP
May 21, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Placebo Response Risks: SueWallSt
May 21, 2026 /PRNewswire/ -- SueWallSt announces that a securities class action has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS).
More news about: SueWallSt.com
May 21, 2026, 09:00 ET Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- HBSS
www.hbsslaw.com/investor-fraud/goss Contact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
May 20, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Clinical Execution Failures: Levi & Korsinsky
Securities Class Action Services' Top 50 Report.Frequently Asked Questions About the GOSS LawsuitQ: Who is eligible to join the GOSS investor lawsuit? A: Investors who purchased GOSS stock or securities between June 16, 2025 and February 20, 2026 and suffered financial losses
More news about: Levi & Korsinsky, LLP
May 19, 2026, 09:00 ET The Gross Law Firm Reminds Gossamer Bio, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 1, 2026 - GOSS
May 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS).
More news about: The Gross Law Firm
May 18, 2026, 23:55 ET GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff deadline.So What: If
More news about: THE ROSEN LAW FIRM, P. A.
May 18, 2026, 12:26 ET GOSS 2-WEEK DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
May 18, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20,
More news about: Hagens Berman Sobol Shapiro LLP
May 14, 2026, 20:02 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GOSS
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 14, 2026, 15:33 ET Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GOSS). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JUNE 1, 2026 (LEAD PLAINTIFF DEADLINE)
More news about: Law Offices of Howard G. Smith
May 14, 2026, 14:27 ET GOSS Investor Alert: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
May 14, 2026, 11:05 ET GOSS INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
May 13, 2026, 15:36 ET Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GOSS).
More news about: Glancy Prongay Wolke & Rotter LLP
May 13, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Trial Prospects: Levi & Korsinsky
seven consecutive years.Frequently Asked Questions About the GOSS LawsuitQ: What is the GOSS class action lawsuit about? A: A securities class action has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) alleging materially false and misleading statements between June 16,
More news about: Levi & Korsinsky, LLP
May 12, 2026, 19:41 ET GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff deadline.So What: If
More news about: THE ROSEN LAW FIRM, P. A.
May 12, 2026, 09:00 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 1, 2026 in Gossamer Bio, Inc. Lawsuit - GOSS
May 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS).
More news about: The Gross Law Firm
May 11, 2026, 12:51 ET Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
May 08, 2026, 15:58 ET Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GOSS) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Gossamer Bio, Inc. of Class Action Lawsuit and Upcoming Deadlines - GOSS
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-gossamer-bio-inc-of-class-action-lawsuit-and-upcoming-deadlines--goss-302765133.htmlSOURCE
More news about: Pomerantz LLP
May 07, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After CEO Allegedly Concealed PROSERA Placebo Risk: SueWallSt
the firm has recovered hundreds of millions of dollars for investors.Frequently Asked Questions About the GOSS LawsuitQ: Who are the defendants named in the GOSS lawsuit? A: The complaint names Gossamer Bio, Inc. and individual defendant Faheem Hasnain, CEO, Chairman, and Co-founder,
More news about: SueWallSt.com
May 06, 2026, 09:00 ET GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing PROSERA Trial Risks: Levi & Korsinsky
2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Gossamer Bio, Inc. (NASDAQ: GOSS) to contact the firm. WHO IS AFFECTED: Those who purchased GOSS securities between June 16, 2025, and February 20, 2026, may be entitled to recover damages.
More news about: Levi & Korsinsky, LLP
May 05, 2026, 22:29 ET GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026.So What: If you purchased Gossamer
More news about: THE ROSEN LAW FIRM, P. A.
May 05, 2026, 13:50 ET Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure- Hagens Berman
www.hbsslaw.com/investor-fraud/gossContact the Firm Now: [email protected] 844-916-0895Gossamer Bio, Inc. (GOSS) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP